WNK2 and neoplasm: HT29 cells harbour mutations that activate the Wnt, mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways, as well as inactivating mutations in the tumour suppressors SMAD4 and TP53 (Ahmed et al., 2013).